What are the age‑based preventive care and screening recommendations for adult women?

Age-Based Preventive Care and Screening Recommendations for Adult Women

Women should undergo cervical cancer screening starting at age 21, breast cancer screening starting at age 45 (with option to begin at 40), colorectal cancer screening starting at age 45, and osteoporosis screening starting at age 65, with specific intervals and methods tailored to each age group.

Cervical Cancer Screening

Ages 21-29 Years

• Begin screening at age 21 years regardless of age of sexual initiation 1, 2
• Screen with cytology alone every 3 years (conventional Pap smear or liquid-based cytology) 1, 2
• Do NOT use HPV testing for screening in this age group (though acceptable as reflex test for ASC-US) 1, 2
• Do NOT screen women younger than 21 years under any circumstances 1, 2

Ages 30-65 Years

• Preferred approach: Co-testing every 5 years (HPV testing + cytology) 1, 2
• Acceptable alternative: Cytology alone every 3 years 1, 2
• Never screen annually with any method 1, 2

Age 65+ Years

• Discontinue screening if adequate prior negative screening: 3 consecutive negative cytology tests OR 2 consecutive negative co-tests within the past 10 years, with most recent test within 5 years 1, 2
• Exception: Women with history of CIN2 or more severe diagnosis should continue screening for at least 20 years, even if this extends beyond age 65 1, 2

Critical Caveat: These recommendations apply only to average-risk women. Do NOT follow these guidelines for women with: history of cervical cancer, DES exposure in utero, immunosuppression (organ transplant, chemotherapy, chronic corticosteroids), or HIV-positive status 1, 2.

Breast Cancer Screening

Ages 40-44 Years

• Women should have the opportunity to begin annual screening (qualified recommendation allowing shared decision-making) 3
• This is optional, not mandatory 4, 3

Ages 45-54 Years

• Screen annually with mammography (strong recommendation) 4, 3
• This represents the ACS's firm position that benefits clearly outweigh harms in this age group 3

Ages 55+ Years

• Transition to biennial screening (every 2 years) OR continue annual screening based on patient preference 4, 3
• Continue screening as long as overall health is good and life expectancy ≥10 years 4, 3

Beyond Age 75 Years

• Base decision on shared decision-making informed by health status and longevity, not age alone 4

Important Note: The ACS does NOT recommend clinical breast examination for screening at any age 4, 3. Breast self-examination is also not recommended due to lack of benefit and risk of false-positives 4.

Divergent Evidence: The American College of Radiology recommends starting annual screening at age 40 4, while the Canadian Task Force recommends against screening women 40-49 years 4. The ACS 2015 guideline 3 represents the most recent comprehensive evidence-based approach balancing benefits and harms.

Colorectal Cancer Screening

Ages 45-75 Years

• Begin regular screening at age 45 years 2
• Choose one of the following options:
  • Annual fecal immunochemical test (FIT), OR
  • Annual high-sensitivity guaiac-based fecal occult blood test, OR
  • Multitarget stool DNA test every 3 years, OR
  • Colonoscopy every 10 years, OR
  • CT colonography every 5 years, OR
  • Flexible sigmoidoscopy every 5 years 2
• All positive non-colonoscopy tests must be followed with timely colonoscopy 2
• Continue through age 75 if life expectancy >10 years 2

Ages 76-85 Years

• Individualize screening decisions based on patient preferences, life expectancy, health status, and prior screening history 2

Osteoporosis Screening

Age 65+ Years

• Screen all women starting at age 65 years with DXA (dual-energy x-ray absorptiometry) 5

Postmenopausal Women <65 Years

• Use 2-step approach: First assess fracture risk with clinical risk assessment tool, then order DXA if elevated risk identified 5
• Screen selectively based on formal clinical risk assessment 5

Screening Interval: Evidence on optimal rescreening intervals is limited; clinical judgment should guide timing of repeat screening 5.

HPV Vaccination

Ages 11-12 Years

• Routine HPV vaccination recommended as primary prevention 1

Ages 13-18 Years

• "Catch-up" vaccination recommended for those who missed earlier vaccination or need to complete series 1

Ages 19-26 Years

• Insufficient data for universal recommendation; individualize based on discussion of prior HPV exposure risk and potential benefit 1

Critical Point: Vaccination status does NOT change cervical cancer screening recommendations—vaccinated women must continue routine screening 1.

Additional Preventive Services (Based on General Medical Knowledge)

All Adult Women

• Blood pressure screening: At every healthcare visit
• BMI/obesity screening: Annually
• Depression screening: Periodically using validated tools
• Intimate partner violence screening: Periodically in safe, confidential setting
• Tobacco use screening and cessation counseling: At every visit
• Alcohol and substance use screening: Periodically

Sexually Active Women <25 Years

• Annual screening for gonorrhea and chlamydia 6

Risk-Based Screening

• HIV screening: At least once; more frequently if high-risk behaviors
• Hepatitis C screening: Birth cohort (1945-1965) and risk-based
• Syphilis and hepatitis B: Individualized based on risk factors 6

Common Pitfalls to Avoid

1. Never screen for cervical cancer before age 21 or after adequate negative screening beyond age 65 (unless high-risk history)
2. Never perform annual cervical cancer screening—this causes more harm than benefit through overdiagnosis and overtreatment
3. Do not use HPV testing in women 21-29 years for primary screening
4. Do not stop cervical cancer screening based on HPV vaccination status
5. Do not perform screening pelvic examinations in asymptomatic women—AAFP recommends against this practice 6
6. Do not base breast cancer screening decisions on clinical breast examination—it is not recommended for screening 4, 3